{"id":"NCT01959334","sponsor":"Eli Lilly and Company","briefTitle":"Evaluate the Immunogenicity of a Novel Glucagon Formulation","officialTitle":"A Single Center, Randomized, Parallel Safety Study To Evaluate The Immunogenicity Of A Novel Glucagon Formulation Compared To Commercially Available Glucagon Administered By Intramuscular Injection In Adults With Type 1 OR Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2013-10-10","resultsPosted":"2019-09-06","lastUpdate":"2019-09-06"},"enrollment":75,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Drug-specific Antibodies","Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Nasal Glucagon (NG)","otherNames":["Nasal Glucagon","AMG504-1 Dry-Mist Intranasal Glucagon","LY900018"]},{"type":"DRUG","name":"Glucagon IM","otherNames":["GlucaGenÂ® HypoKit"]}],"arms":[{"label":"Glucagon IM","type":"ACTIVE_COMPARATOR"},{"label":"Nasal Glucagon (NG","type":"EXPERIMENTAL"}],"summary":"This study provides information on immunogenicity of Nasal Glucagon (AMG504-1) with regards to the potential development of treatment-emergent anti-glucagon antibodies.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Anti-Drug Antibody (ADA)","timeFrame":"Baseline through study completion (up to 10 weeks)","effectByArm":[{"arm":"Glucagon IM","deltaMin":0,"sd":null},{"arm":"Nasal Glucagon (NG)","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["Lacrimation increased","Headache","Ocular hyperaemia","Rhinorrhoea","Nasal discomfort"]}}